NEWS IN BRIEF
Glenmark opts for Horizon’s gene edited cell lines
Glenmark signs a full commercial license to utilize Horizon’s gene edited CHO cell lines to be added to the former’s biomanufacturing process.
Archives for October 1, 2019
CureDuchenne backs immune-resistant AAV gene therapy platform
CureDuchenne invests in Evader, a gene therapy platform created by Chameleon, which bypasses the immune responses obstructing repeated dosing.